Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:36 AM
Ignite Modification Date:
2025-12-25 @ 12:36 AM
NCT ID:
NCT06001567
Eligibility Criteria:
Inclusion Criteria:
* HCC with diagnosis confirmed pathologically or clinically
* Patients who need to receive TACE and/or HAIC, or have plans to undergo another treatment (3-6 weeks after the previous treatment)
* Child Pugh class A or B
* ECOG PS 0-2
* PLT ≤ 75×10\^9/L (10 days before interventional therapy)
Exclusion Criteria:
* Thrombocytopenia caused by hematological diseases, non chemotherapy related thrombocytopenia (excluding liver cirrhosis with hypersplenism)
* PLT \<30×10\^9/L
* History of hepatic encephalopathy, refractory ascites, or hepatorenal syndrome
* History of arterial or venous thrombosis within 6 months
* Uncontrolled severe infections
* Pregnant or breastfeeding female patients
* Immune deficiencies, such as autoimmune diseases, HIV infected individuals, etc
* Anticoagulation or antiplatelet therapy witch cannot be suspended during the treatment period: heparin, warfarin, rivaroxaban, dipyridamole, non-steroidal anti-inflammatory drugs, aspirin, verapamil, Ticlopidine, clopidogrel, glycoprotein IIb/IIIa antagonists, erythropoietin, etc;
* Administration of blood products within 7 days prior to the baseline visit (excluding albumin infusion)
* Allergy to avatrombopag or any of its formulations
* History (such as gastrointestinal bleeding within 3 months, high risk of thrombosis, such as portal vein main flow velocity\<10cm/s) which may affect the safety of the patients or their ability to complete the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06001567
Study Brief:
Protocol Section:
NCT06001567